Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00568997 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Study acronym: PEER
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2026 to Dec 2027 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 2026 to Jun 2028 · Site details revisedv21 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 2026 to Jun 2028
    • Site details revised
  2. 5 versions Re-verified since Nov 21, 2019, no change to tracked fieldsv16-v20
  3. Study description expanded, about 20 wordsv15 See this version in full on ClinicalTrials.gov ↗
  4. Primary and study completion dates: Dec 2021 to Dec 2026 Start date: Jun 2004 to Jun 27, 2005v14 Show 1 more changeShow less
    • Start date: Jun 2004 to Jun 27, 2005
  5. Primary completion date: Dec 2021v13
Show 11 earlier versionsHide 11 earlier versions
  1. Re-verified, no change to tracked fieldsv12
  2. Study Status, Referencesv11
  3. Lead sponsor: Novartis to Bausch Health Americas, Inc. Enrollment target: 4000 to 8000 · Primary endpoint revised · Completion date: Apr 2018 to Dec 2021 · 3 morev10 Show 6 more changesShow less
    • Enrollment target: 4000 to 8000
    • Primary endpoint revised
    • Completion date: Apr 2018 to Dec 2021
    • Eligibility criteria shortened, about 6 words
    • Secondary endpoints revised (3)
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv9
  5. Site contact updatedv8
  6. 4 versions Re-verified since Feb 8, 2008, no change to tracked fieldsv4-v7
  7. Completion date: Apr 2018 Start date: Nov 2004 to Jun 2004v3 Show 1 more changeShow less
    • Start date: Nov 2004 to Jun 2004
  8. Secondary endpoints revised (3)v2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
Trial Details
NCT Number NCT00568997
Lead Sponsor Bausch Health Americas, Inc.
Collaborators: Clinical Research Computing Unit (University of Pennsylvania)
Conditions Atopic Dermatitis
Enrollment 8,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov